Do I need to exercise on Wegovy?

Yes — resistance training specifically. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Cardio is a bonus; resistance is the non-negotiable.

How fast do results show on GLP-1?

Appetite changes in 1-2 weeks. Visible weight loss usually starts in week 4-6. Significant fat loss accelerates in weeks 12-44 as the dose escalates.

Why am I not losing weight on Wegovy?

Most non-responders fall into 4 buckets: dose hasn't reached maintenance (2.4 mg), titration was interrupted, calorie intake creeps to match satiety, or a hormonal/medical confounder (hypothyroid, PCOS-with-insulin-resistance, sleep apnea). Talk to your prescriber if no measurable loss by week 16 at maintenance dose.

Can I build muscle on a GLP-1?

Yes — with deliberate resistance training and adequate protein. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Lifting 2-3x/week + 1.2-1.6 g/kg ideal-body-weight protein preserves and can grow muscle while losing fat.

Can GLP-1 help with PCOS?

Yes — primarily via weight loss and improved insulin sensitivity. Smaller trials show improved ovulatory cycles and reduced androgen symptoms in women with PCOS. No GLP-1 is FDA-approved for PCOS; use is off-label and weight-driven.

Does GLP-1 work for type 1 diabetes?

No GLP-1 is FDA-approved for type 1 diabetes. Some endocrinologists prescribe semaglutide off-label as an insulin adjunct in T1D with obesity or insulin resistance, but evidence is limited and DKA risk during gastric-emptying changes requires careful monitoring.

ICD-10 · K76.0

NAFLD / MASH(NAFLD)

Non-alcoholic fatty liver disease (NAFLD), now often called metabolic dysfunction-associated steatotic liver disease (MASLD), is the most common chronic liver disease in the US. The progressive inflammatory form (MASH, formerly NASH) can lead to cirrhosis. GLP-1 medications show emerging benefit for both weight loss and direct liver effects.

Medically reviewed by Dr. Jane Novak, MD, MPH on June 1, 2026

This is general health information, not medical advice. Talk to a licensed clinician about diagnosis and treatment options.

Overview

NAFLD/MASLD affects roughly 25-30% of US adults and is strongly linked to obesity and type 2 diabetes. Most cases are silent — discovered incidentally on imaging or labs (elevated ALT/AST). The progressive inflammatory form, MASH (metabolic dysfunction-associated steatohepatitis), can advance to fibrosis and cirrhosis over years. Treatment focuses on metabolic root causes: weight loss of 7-10% can reverse early MASH. The 2024 ESSENCE trial showed semaglutide 2.4 mg reduced MASH histology in adults with biopsy-proven disease. As of 2025, resmetirom (Rezdiffra) is the first FDA-approved MASH-specific drug, but GLP-1 medications are increasingly part of management plans.

Symptoms

Often asymptomatic
Fatigue
Right upper quadrant discomfort
Elevated liver enzymes (ALT/AST)

Risk factors

Obesity
Type 2 diabetes
Metabolic syndrome
Insulin resistance
Sleep apnea
PCOS

Treatment options

Weight loss (7-10% body weight)
GLP-1 receptor agonists
Resmetirom (Rezdiffra, MASH-specific)
Vitamin E (non-diabetic MASH)
Treat underlying conditions

GLP-1 evidence for NAFLD/MASH

Editorial grades summarizing study quality and convergence. How we grade.

Claim	Grade	Basis
Semaglutide resolves NASH without worsening fibrosis Source: NEJM, 2021 (opens in a new tab) Phase 2 RCT (n=320, 72 weeks); ~59% resolution vs 17% placebo at 0.4 mg	BModerate evidence	Phase 2 RCT (n=320, 72 weeks); ~59% resolution vs 17% placebo at 0.4 mg
Tirzepatide reduces liver fat in adults with T2D + steatosis Source: Lancet Diabetes & Endocrinology, 2022 (opens in a new tab) SURPASS-3 MRI sub-study showed liver-fat reduction dose-dependent	BModerate evidence	SURPASS-3 MRI sub-study showed liver-fat reduction dose-dependent
GLP-1 reverses advanced (F3-F4) fibrosis Some trial signal; phase 3 (ESSENCE) ongoing, results pending	CLimited evidence	Some trial signal; phase 3 (ESSENCE) ongoing, results pending
GLP-1 is FDA-approved for MASH No GLP-1 currently FDA-approved for MASH; resmetirom (Rezdiffra) is the only approved drug class	FNo evidence	No GLP-1 currently FDA-approved for MASH; resmetirom (Rezdiffra) is the only approved drug class

Not sure which medication is right for you? Our quiz matches you with providers based on state, insurance, and budget.

Take the GLP-1 quiz

Common questions readers ask

Do I need to exercise on Wegovy?: Yes — resistance training specifically. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Cardio is a bonus; resistance is the non-negotiable.
How fast do results show on GLP-1?: Appetite changes in 1-2 weeks. Visible weight loss usually starts in week 4-6. Significant fat loss accelerates in weeks 12-44 as the dose escalates.
Why am I not losing weight on Wegovy?: Most non-responders fall into 4 buckets: dose hasn't reached maintenance (2.4 mg), titration was interrupted, calorie intake creeps to match satiety, or a hormonal/medical confounder (hypothyroid, PCOS-with-insulin-resistance, sleep apnea). Talk to your prescriber if no measurable loss by week 16 at maintenance dose.
Can I build muscle on a GLP-1?: Yes — with deliberate resistance training and adequate protein. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Lifting 2-3x/week + 1.2-1.6 g/kg ideal-body-weight protein preserves and can grow muscle while losing fat.
Can GLP-1 help with PCOS?: Yes — primarily via weight loss and improved insulin sensitivity. Smaller trials show improved ovulatory cycles and reduced androgen symptoms in women with PCOS. No GLP-1 is FDA-approved for PCOS; use is off-label and weight-driven.
Does GLP-1 work for type 1 diabetes?: No GLP-1 is FDA-approved for type 1 diabetes. Some endocrinologists prescribe semaglutide off-label as an insulin adjunct in T1D with obesity or insulin resistance, but evidence is limited and DKA risk during gastric-emptying changes requires careful monitoring.

Sources

AASLD Practice Guidance on the Diagnosis and Management of NAFLD (opens in a new tab) — American Association for the Study of Liver Diseases
Semaglutide in patients with MASH (opens in a new tab) — NEJM

Was this page helpful?

NAFLD / MASH(NAFLD)

Overview

Symptoms

Risk factors

Treatment options

GLP-1 evidence for NAFLD/MASH

Related GLP-1 medications

Mounjaro

Ozempic

Wegovy

Zepbound

Common questions readers ask

Sources